Getting Your Asset into the Global Market: Regulatory, Clinical and Commercial Considerations

Life Sciences, Clinical Trials, Commercialization & HEOR, Emerging Market,
  • Thursday, October 27, 2022

Despite recession risk, global biopharmaceutical markets continue to grow and remain a desirable option for APAC-based companies. However, recent examples of Chinese asset rejections by the US Food & Drug Administration — largely due to insufficient patients in the US as well as lack of diversity of patients — underscores the need for companies to plan for global multiregional clinical trials. Meanwhile, increasing use of health technology assessments (HTA) across key markets including Europe and Japan suggests that proving a significant level of efficacy against existing comparators, rather than placebo, is becoming more important. Furthermore, as therapy areas become increasingly more crowded and commoditized, having a broad clinical and commercial strategy is unlikely to pay off.

Thus, companies increasingly face difficulties designing their global multiregional clinical trials in a way that corresponds to the needs of global regulators and optimizes the overall commercial success of products in global biopharmaceutical markets — all while minimizing costs associated with their clinical trial programs. There is therefore a growing need to re-evaluate trial design strategies to not only meet approval requirements, but also drive product market uptake and overall commercial success. This requires early engagement with regulatory bodies addressing important topics such as endpoints and standard of care for control arms, as well as making accommodations for payer preferences through levers like more precise exclusion and inclusion criteria.

This webinar will cover key considerations for developing strategic and optimized global multiregional clinical trials. Register to learn how addressing regulatory, pricing, market access and commercial strategy considerations early in the clinical development planning and design process can help support future commercial success for APAC-developed assets on the global stage.


Joy Chen

Joy Chen, PhD, EMBA, APAC Regulatory Lead & Head of China, Global Regulatory Affairs Solutions, Syneos Health

Joy holds a PhD in pharmacology from the US and has 20 years’ experience in regulatory affairs. Joy leads regulatory strategy and implementation for the APAC region and engages in product lifecycle management. Her extensive therapeutic area background includes oncology, CNS, respiratory, infectious disease, immunology, CV and diabetics/metabolism as well as medical devices/diagnostics, advanced therapies and rare disease.

Message Presenter

Anthony Messina, PhD(c), MSc, CCRP, Director, Assessment & Insights Learning Solutions, Syneos Health

Anthony Messina is an experienced clinical research scientist and professional within the pharmaceutical research industry. In his current role at Syneos Health, Anthony provides medical affairs support, auditing, training and oversight for industry, academic, and government-sponsored clinical trials phase I, II, and III.


Anthony’s work supports the development of new and ongoing clinical research projects, while working collaboratively to oversee and manage the success of clinical research programs. Previously, Anthony has served as a Sr. Clinical Research Associate, Clinical Research Manager, Medical Writer, Clinical Research Coordinator, Clinical Research Scientist, and Medical Education Coordinator. Mr. Messina contributes toward the development and endpoint evaluation of multiple clinical studies and has focused on research dealing with the treatment and management of hematological neoplasms, such as Myelodysplastic syndromes and Acute Myeloid Leukemia.

Read Less...

Message Presenter
Khalil-Ahmed, Syneos

Khalil Ahmed, VP Medical Affairs, Europe, Syneos Health

Khalil is responsible for Syneos Health Deployment Solutions Medical Affairs strategy and operations with a particular focus on driving quality and excellence among Field Medical Teams for its clients in all stage of product life cycle.

Khalil possess extensive experience in supporting clinical development, new product launch excellence, patient journey, product and brand Management, integrated commercial model design, operational excellence, who has been working with products in different stages of their life cycle in broad range of therapeutic areas including Immunology, Oncology, CNS, Rare Diseases, Renal, Cardiovascular, Infectious Diseases, Urology, Diabetes, Vaccines among others


Prior to joining Syneos Health Deployment Solutions, Europe Khalil has worked as Head of Medical Affairs in Syner-Med (PP) Ltd. overseeing Medical and Regulatory Affairs. Previously he served as a strategic lead for Shire Field Based Medicine (FBM) Service RoW (Ex-US) across the product portfolio. Before Shire’s takeover of Viropharma he worked as Medical Science Manager in UK/BeNeLux/Ire responsible for both Medical Affairs strategy & planning and MSL team. Earlier Khalil worked in AstraZeneca for number of years in Medical Affairs Department in the UK.

Read Less...

Message Presenter
Stacey Fergusson

Stacey Fergusson, Senior Director, Corporate Development, Illingworth Research Group – a Syneos Health Company

Stacey has over 13 years’ experience in a variety of roles encompassing global Project Management, Outsourcing, Contracting, Vendor Management and Corporate Development.  She has led the set-up, implementation and oversight of clinical programs, operational teams and strategic partnerships across APAC.  In her current role, Stacey is responsible for leading Illingworth’s global business expansion and Vendor Management functions.  Stacey holds a BSc and PhD in microbial genetics from the University of York, UK, and has a passion for travel, particularly within the APAC region.

Message Presenter
Chris Wells

Chris Wells, Senior Director, Patient Concierge, Illingworth Research Group – a Syneos Health Company

Chris Wells leads Illingworth Research’s patient concierge division, PatientGO, supporting sites and patients with travel, accommodation and expense reimbursement services.

Message Presenter
Rosanne Campbell

Rosanne Campbell, Senior Project Leader, Value, Access & HEOR, Syneos Health Consulting

Rosanne Campbell is senior project leader for value, access and HEOR at Syneos Health Consulting, based in London. Rosanne brings more than eight years of experience in HEOR and PMA consulting to Syneos Health’s Pricing and Market Access practice in Europe. She has worked on a wide range of projects including economic models, literature reviews, reimbursement dossiers and market access strategy across Europe, Asia and the US. Rosanne studied in Ireland and London with degrees in Business, Economics and Health Economics.

Message Presenter

Who Should Attend?

This session would be of interest to biopharma executives in APAC involved in:

  • Commercial Ops
  • Strategy
  • Clinical Development
  • Clinical Ops
  • Regulatory
  • Vendor Management
  • Marketing
  • Pricing and Market Access
  • Medical Affairs

Xtalks Partner

Syneos Health

Syneos Health® (Nasdaq: SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically blending clinical development, medical affairs, and commercial capabilities to address modern market realities.

Together we share insights, use the latest technologies, and apply advanced business practices to speed our customers’ delivery of important therapies to patients. We support a diverse, equitable and inclusive culture.

To learn more about how we are shortening the distance from lab to life®, visit or subscribe to our podcast.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account